CGEM 8-K: SEC filing

Filed with the SEC on Nov 10, 2026 · accession 0001193125-26-454408

CGEM filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Cullinan Therapeutics furnished its quarterly financial results for the three and nine months ended September 30, 2026 via an 8-K Item 2.02 disclosure and accompanying press release.

For details, click here →How to read a 8-K →

Key details

RegistrantCullinan Therapeutics, Inc.

Chief financial officerMary Kay Fenton

✦ Ask GOAX AI about this filing — what it means for CGEM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CGEM?

Click here

Frequently asked questions

What did CGEM file with the SEC on Nov 10, 2026?

CGEM filed a 8-K (SEC filing). Cullinan Therapeutics furnished its quarterly financial results for the three and nine months ended September 30, 2026 via an 8-K Item 2.02 disclosure and accompanying press release.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other CGEM SEC filings

Get alerts when CGEM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

CGEM overview CGEM analysis CGEM news Latest SEC filings